



SPEAKER PROFILES

19 May

Refractory high-risk neuroblastoma management

Alba Rubio



My name is Alba Rubio, I am a young Spanish paediatric oncologist. Since I finished my training in paediatric in 2018, I have been working as a clinical researcher fellowship in the Haemato-Oncology Clinical Trials Unit in Niño Jesus Hospital in Madrid, Spain. I have special interest in neoplasia that relapse or are refractory to the first line of treatment and I am sensitized with the difficult access to new therapies for paediatric patients. Currently, I am carrying out my PhD about toxicities and quality of life in children with advance tumours at the Autónoma University of Madrid.

Ruth Ladenstein



Ruth Ladenstein is Professor in Paediatrics and Senior Consultant for Paediatric Haematology and Oncology at the St. Anna Children's Hospital. She is Head of the Clinical Trials Unit S2IRP (Studies & Statistics for Integrated Research and Projects) at the Children's Cancer Research Institute (CCRI) of the St. Kinderkrebsforschung e.V. (<http://science.ccri.at/>).